|
|
|
| Meta-analysis of the effect of intravenous iron in the treatment of heart failure with iron deficiency |
| HE Wei-feng LI Zhi-feng▲ WU Hong-lian |
| Department of Cardiology, Yongchuan Hospital Affiliated to Chongqing Medical University, Chongqing 402160, China |
|
|
|
|
Abstract Objective To systematically evaluate the effect of intravenous iron in the treatment of heart failure (HF)with rion deficiency (ID).Methods PubMed, the Cochrane Library (issue 5, 2018), Embase, CNKI, Wanfang databases were searched by the computer to collect the related randomized controlled trials (RCTs) about intravenous iron in the treatment of HF with ID, the time limit of retrieval was to build the database until May 2018.Two investigators independently screened the literatures and extracted data according to the inclusion and exclusion criteria, and assessed the risk of bias in the included studies.Then, meta-analysis was performed by Stata 12.0 software.Results A total of 10 RCTs involving 1294 patients were included.The results showed that, compared with placebo, intravenous iron treatment for HF with ID could effectively reduce all-cause death or cardiovascular hospitalization rate (OR=0.45,95%CI[0.31-0.65], P=0.000), cardiovascular death or worsening heart failure hospitalization rate (OR=0.49, 95%CI [0.33-0.75], P=0.001), and HF hospitalization rate (OR=0.46，95%CI [0.30-0.71], P=0.000).Also, intravenous iron therapy could increase the patients′ 6-minute walking test distance (SMD=2.34, 95%CI[0.69-3.99], P=0.005).However, there were no significant differences between both groups in all-cause death rate (OR=0.75, 95%CI [0.41-1.36], P=0.338),cardiovascular death rate (OR=1.29, 95%CI [0.72-2.34], P=0.393] and LVEF (SMD=1.02, 95%CI [-0.59-2.63], P=0.213).Conclusion For patients with HF with ID, intravenous iron supplementation is beneficial to improve exercise tolerance and reduce the HF hospitalization rate.
|
|
|
|
|
|
|
|
|
